TABLE 4.
Log‐rank and Cox multivariate analyses of factors associated with PFS of patients
| Factors | HR (95% CI) | Log‐rank analysis p value | HR (95% CI) | Cox multivariate analysis p value |
|---|---|---|---|---|
| Age group (<65 vs. ≥65 years) | 0.8109 (0.3971–1.656) | 0.5292 | ||
| DFI (≤12 vs. >12 months) | 1.463 (0.8458–2.530) | 0.1330 | ||
| Hormone receptor status (HR+ vs. HR−) | 1.286 (0.8412–1.965) | 0.2621 | ||
| HER2 status (HER2+ vs. HER2 overexpression) | 1.537 (0.8482–2.786) | 0.0954 | 1.504 (0.881–2.566) | 0.134 |
| Prior treated by lapatinib (yes vs. no) | 1.895 (1.123–3.198) | 0.0036 | 1.786 (1.134–2.810) | 0.012 |
| Treatment lines for pyrotinib at metastatic setting (1 vs. 2 vs. ≥3) | 0.0262 | 0.092 | ||
| 1 vs. 2 | 0.4657 (0.2448–0.8857) | 0.0339 | ||
| 1 vs. ≥3 | 0.3971 (0.2311–0.6822) | 0.0075 | ||
| ≤2 vs. >2 | 0.6532 (0.4348–0.9814) | 0.0388 | ||
| CEA status (CEA+ vs. CEA−) | 1.366 (0.8076–2.310) | 0.2235 | ||
| CA153 status (CA153+ vs. CA153−) | 1.338 (0.8090–2.213) | 0.2450 | ||
| Number of metastatic sites (≤2 vs. >2) | 0.4753 (0.2091–1.081) | 0.1906 | 0.870 (0.251–3.021) | 0.827 |
| Site of metastasis (visceral vs. nonvisceral) | 2.062 (1.276–3.333) | 0.0138 | 2.008 (1.057–3.812) | 0.033 |
| Brain metastases (yes vs. no) | 1.484 (0.9477–2.323) | 0.0622 | 1.259 (0.803–1.973) | 0.316 |
| Lung metastases (yes vs. no) | 1.046 (0.6928–1.579) | 0.8290 | ||
| Liver metastases (yes vs. no) | 1.634 (1.074–2.487) | 0.0151 | 1.195 (0.760–1.880) | 0.440 |
| Types of trastuzumab resistance (primary vs. secondary) | 0.9747 (0.6109–1.555) | 0.9141 | ||
| TP53 status (TP53+ vs. TP53−) | 0.7480 (0.3814–1.467) | 0.3624 |
Entries in bold represent statistically significant.
Abbreviations: CI, confidence interval; HR, hormone receptor; PFS, progression‐free survival.